Shares of several obesity-focused stocks dropped on Wednesday after Swiss pharma giant Roche (RHHBY) announced positive top-line results from an early-stage study on its experimental obesity drug CT-996.Data from the early stage showed that this once-daily, orally-administered Roche drug resulted in a clinically meaningful placebo-adjusted mean weight loss of 6.1% within four weeks in obesity patients without type II diabetes (T2D).This is the second positive data readout from Roche in less than three month ...